相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update
Monica R. Gadelha et al.
ENDOCRINE REVIEWS (2019)
Pituitary Diseases and Bone
Gherardo Mazziotti et al.
ENDOCRINE REVIEWS (2018)
Somatostatin Analogs and Glucose Metabolism in Acromegaly: A Meta-Analysis of Prospective Interventional Studies
Alessia Cozzolino et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
A Consensus Statement on acromegaly therapeutic outcomes
Shlomo Melmed et al.
NATURE REVIEWS ENDOCRINOLOGY (2018)
Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study
Eva Lesen et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly
Nicholas A. Tritos et al.
PITUITARY (2017)
The role of combination medical therapy in the treatment of acromegaly
Dawn Shao Ting Lim et al.
PITUITARY (2017)
Acromegaly at diagnosis in 3173 patients from the Liege Acromegaly Survey (LAS) Database
Patrick Petrossians et al.
ENDOCRINE-RELATED CANCER (2017)
Quality of life tools for the management of pituitary disease
Susan M. Webb et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry
Luigi Maione et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
Biochemical investigations in diagnosis and follow up of acromegaly
Katharina Schilbach et al.
PITUITARY (2017)
Somatostatin receptor ligands in the treatment of acromegaly
Monica R. Gadelha et al.
PITUITARY (2017)
Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities
Rosario Pivonello et al.
PITUITARY (2017)
Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement
Felipe F. Casanueva et al.
PITUITARY (2017)
The association between biochemical control and cardiovascular risk factors in acromegaly
John D. Carmichael et al.
BMC ENDOCRINE DISORDERS (2017)
Pegvisomant in acromegaly: an update
A. Giustina et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2017)
Impaired quality of life in patients with treated acromegaly despite long-term biochemically stable disease: Results from a 5-years prospective study
Nikolaos Kyriakakis et al.
CLINICAL ENDOCRINOLOGY (2017)
Biochemical assessment of disease control in acromegaly: reappraisal of the glucose suppression test in somatostatin analogue (SA) treated patients
Mai Christiansen Arlien-Soborg et al.
ENDOCRINE (2017)
Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly
Renata S. Auriemma et al.
ENDOCRINE (2017)
Morphometric changes correlate with poor psychological outcomes in patients with acromegaly
Syed Ali Imran et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
Bone and Joint Disorders in Acromegaly
Kim M. J. A. Claessen et al.
NEUROENDOCRINOLOGY (2016)
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Annamaria Colao et al.
PITUITARY (2016)
Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR
Susan L. Samson
DRUGS (2016)
Treatment of acromegaly increases BMD but reduces trabecular bone score: a longitudinal study
Kristin Godang et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
Disease activity and lifestyle influence comorbidities and cardiovascular events in patients with acromegaly
Chiara Sardella et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2016)
Evolution of Glucose Tolerance After Treatment of Acromegaly: A Study in 57 Patients
C. Jonas et al.
HORMONE AND METABOLIC RESEARCH (2016)
The Mexican Acromegaly Registry: Clinical and Biochemical Characteristics at Diagnosis and Therapeutic Outcomes
Lesly A. Portocarrero-Ortiz et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
The risks of overlooking the diagnosis of secreting pituitary adenomas
Thierry Brue et al.
ORPHANET JOURNAL OF RARE DISEASES (2016)
Low frequency of cardniac arrhythmias and lack of structural heart disease in medically-na⟨ve acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment
Leila Warszawski et al.
PITUITARY (2016)
Challenges in the diagnosis and management of acromegaly: a focus on comorbidities
Alin Abreu et al.
PITUITARY (2016)
Clinical importance of achieving biochemical control with medical therapy in adult patients with acromegaly
Elena A. Christofides
PATIENT PREFERENCE AND ADHERENCE (2016)
Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters
Victor J. Geraedts et al.
FRONTIERS IN ENDOCRINOLOGY (2016)
Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center
Susanna Bacigaluppi et al.
ENDOCRINE (2016)
Treatment of acromegaly in the era of personalized and predictive medicine
Manuel Puig Domingo
CLINICAL ENDOCRINOLOGY (2015)
Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study
Emmanuelle Kuhn et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Persistent negative illness perceptions despite long-term biochemical control of acromegaly: novel application of the drawing test
Jitske Tiemensma et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Low Frequency of Cardiomyopathy Using Cardiac Magnetic Resonance Imaging in an Acromegaly Contemporary Cohort
Cintia Marques dos Santos Silva et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Bone Turnover, Bone Mineral Density, and Fracture Risk in Acromegaly: A Meta-Analysis
Gherardo Mazziotti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Erectile Dysfunction Is Common among Men with Acromegaly and Is Associated with Morbidities Related to the Disease
Francesco Lotti et al.
JOURNAL OF SEXUAL MEDICINE (2015)
Increased Short-Term Beat-To-Beat Variability of QT Interval in Patients with Acromegaly
Andrea Orosz et al.
PLOS ONE (2015)
Health outcomes in acromegaly: depression and anxiety are promising targets for improving reduced quality of life
Victor Jacobus Geraedts et al.
FRONTIERS IN ENDOCRINOLOGY (2015)
Heart rate variability is reduced in acromegaly patients and improved by treatment with somatostatin analogues
A. Comunello et al.
PITUITARY (2015)
Disease control and treatment modalities have impact on quality of life in acromegaly evaluated by Acromegaly Quality of Life (AcroQoL) Questionnaire
Silvia Vandeva et al.
ENDOCRINE (2015)
Three noninvasive methods in the evaluation of subclinical cardiovascular disease in patients with acromegaly: epicardial fat thickness, aortic stiffness and serum cell adhesion molecules
Oya Topaloglu et al.
CLINICAL ENDOCRINOLOGY (2014)
The beneficial effect of acromegaly control on blood pressure values in normotensive patients
Chiara Sardella et al.
CLINICAL ENDOCRINOLOGY (2014)
Lanreotide Autogel®: A Review of its Use in the Treatment of Patients with Acromegaly
Celeste B. Burness et al.
DRUGS (2014)
Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis
John D. Carmichael et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Acromegaly: An Endocrine Society Clinical Practice Guideline
Laurence Katznelson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
A. Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Successful Mortality Reduction and Control of Comorbidities in Patients With Acromegaly Followed at a Highly Specialized Multidisciplinary Clinic
Moises Mercado et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
EXPERT CONSENSUS DOCUMENT A consensus on the medical treatment of acromegaly
Andrea Giustina et al.
NATURE REVIEWS ENDOCRINOLOGY (2014)
Increased clinical symptoms of acromegalic arthropathy in patients with long-term disease control: a prospective follow-up study
K. M. J. A. Claessen et al.
PITUITARY (2014)
Impact of treatment satisfaction on quality of life of patients with acromegaly
Hasan Kepicoglu et al.
PITUITARY (2014)
Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline
A. Giustina et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2014)
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial
Monica R. Gadelha et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction
Marta Ragonese et al.
ENDOCRINE (2014)
Self-perception of cognitive function among patients with active acromegaly, controlled acromegaly, and non-functional pituitary adenoma: a pilot study
Chris G. Yedinak et al.
ENDOCRINE (2014)
Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register
Christof Schoefl et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013)
Effects of medical therapies for acromegaly on glucose metabolism
C. Urbani et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013)
A Comprehensive Study of Clinical, Biochemical, Radiological, Vascular, Cardiac, and Sleep Parameters in an Unselected Cohort of Patients With Acromegaly Undergoing Presurgical Somatostatin Receptor Ligand Therapy
Anand K. Annamalai et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Place of Preoperative Treatment of Acromegaly with Somatostatin Analog on Surgical Outcome: A Systematic Review and Meta-Analysis
Francisco Pita-Gutierrez et al.
PLOS ONE (2013)
Does hormonal control obviate positive airway pressure therapy in acromegaly with sleep-disordered breathing?
Muhammed Emin Akkoyunlu et al.
RESPIRATORY MEDICINE (2013)
QT dispersion in patients with acromegaly
Mustafa Unubol et al.
ENDOCRINE (2013)
Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study
K. M. J. A. Claessen et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2012)
Evaluation of Left Ventricular Diastolic Function According to New Criteria and Determinants in Acromegaly
Bahri Akdeniz et al.
INTERNATIONAL HEART JOURNAL (2012)
Improvement of cardiac parameters in patients with acromegaly treated with medical therapies
Annamaria Colao
PITUITARY (2012)
The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly
C. N. Jayasena et al.
CLINICAL ENDOCRINOLOGY (2011)
Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone
Aart-Jan van der Lely et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Hypothesis: Extra-hepatic acromegaly: a new paradigm?
Sebastian J. Neggers et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Cotreatment with Pegvisomant and a Somatostatin Analog (SA) in SA-Responsive Acromegalic Patients
Michael Madsen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Affected Illness Perceptions and the Association with Impaired Quality of Life in Patients with Long-Term Remission of Acromegaly
Jitske Tiemensma et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Place of Cabergoline in Acromegaly: A Meta-Analysis
Laure Sandret et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Clinical, quality of life, and economic value of acromegaly disease control
A. Ben-Shlomo et al.
PITUITARY (2011)
Octreotide Long-Acting Release (LAR) A Review of its Use in the Management of Acromegaly
Lily P. H. Yang et al.
DRUGS (2010)
Cardiovascular Risk Factors in Patients with Uncontrolled and Long-Term Acromegaly: Comparison with Matched Data from the General Population and the Effect of Disease Control
Christian Berg et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Effects of somatostatin analogues on acromegalic cardiomyopathy: Results from a prospective study using cardiac magnetic resonance
F. Bogazzi et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2010)
Ultrasound of peripheral nerves in acromegaly: changes at 1-year follow-up
Eugenia Resmini et al.
CLINICAL ENDOCRINOLOGY (2009)
Pituitary-independent effect of octreotide on IGF1 generation
Ana Pokrajac et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies
Gherardo Mazziotti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study
Annamaria Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
The Utility of Oral Glucose Tolerance Testing for Diagnosis and Assessment of Treatment Outcomes in 166 Patients with Acromegaly
John D. Carmichael et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
GH and IGF-I excess control contributes to blood pressure control: results of an observational, retrospective, multicentre study in 105 hypertensive acromegalic patients on hypertensive treatment
Annamaria Colao et al.
CLINICAL ENDOCRINOLOGY (2008)
Growth hormone, insulin-like growth factors, and the skeleton
Andrea Giustina et al.
ENDOCRINE REVIEWS (2008)
A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly
I. M. Holdaway et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease
Maria Vittoria Davi et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance
Maria P. Matta et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR®
Evelyn Oliveira Machado et al.
GROWTH HORMONE & IGF RESEARCH (2008)
A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients
I. Halperin et al.
HORMONE AND METABOLIC RESEARCH (2008)
Divergence between growth hormone and insulin-like growth factor-I concentrations in the follow-up of acromegaly
Orsalia Alexopoulou et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant
S. J. C. M. M. Neggers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Ultrasound measurement of median and ulnar nerve cross-sectional area in acromegaly
Alberto Tagliafico et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy
Annamaria Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly
Laura De Marinis et al.
PITUITARY (2008)
Risk factors for development of coronary heart disease in patients with acromegaly: A five-year prospective study
Fausto Bogazzi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Health-related quality of life in AcroBel, the Belgian Registry acromegalic subjects: data from on acromegaly
Guy T'Sjoen et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Treatment of acromegaly improves quality of life, measured by AcroQol
Angela N. Paisley et al.
CLINICAL ENDOCRINOLOGY (2007)
Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice
A. Pokrajac et al.
CLINICAL ENDOCRINOLOGY (2007)
Impact of somatostatin analogs on the heart in acromegaly: A metaanalysis
Patrick Maison et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion:: An in vitro study on isolated human pancreatic islets
Vandana Singh et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Treatment with growth hormone receptor antagonist in acromegaly: Effect on cardiac structure and performance
Rosario Pivonello et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA
Laura De Marinis et al.
PITUITARY (2007)
Medical progress: Acromegaly
Shlomo Melmed
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly
Shih-Che Hua et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients
Letizia Maria Fatti et al.
CLINICAL ENDOCRINOLOGY (2006)
Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation
AA van der Klaauw et al.
GROWTH HORMONE & IGF RESEARCH (2006)
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on lGF-I levels, tumor mass, hypertension and glucose tolerance
A Colao et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Medical treatment of acromegaly: Comorbidities and their reversibility by somatostatin analogs
George Tolis et al.
NEUROENDOCRINOLOGY (2006)
Increased prevalence of radiological spinal deformities in active acromegaly: A cross-sectional study in postmenopausal women
S Bonadonna et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant
AL Barkan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist
JOL Jorgensen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Late potentials and ventricular arrhythmias in acromegaly
P Maffei et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2005)
Long-acting somatostatin analog therapy of acromegaly: A meta- analysis
PU Freda et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL)
R Trepp et al.
CLINICAL ENDOCRINOLOGY (2005)
Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly
WW de Herder et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly
NR Biermasz et al.
GROWTH HORMONE & IGF RESEARCH (2005)
Morbidity after long-term remission for acromegaly: Persisting joint-related complaints cause reduced quality of life
NR Biermasz et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly
JJ Puder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly
N Karavitaki et al.
CLINICAL ENDOCRINOLOGY (2005)
Factors influencing mortality in acromegaly
IM Holdaway et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Systemic complications of acromegaly: Epidemiology, pathogenesis, and management
A Colao et al.
ENDOCRINE REVIEWS (2004)
Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system
F Minuto et al.
CLINICAL ENDOCRINOLOGY (2004)
Increased prevalence of regurgitant valvular heart disease in acromegaly
AM Pereira et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
High prevalence of cardiac valve disease in acromegaly: An observational, analytical, case-control study
A Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide
A Colao et al.
CLINICAL ENDOCRINOLOGY (2003)
Twelve months of treatment with octreotide-LAR reduces joint thickness in acromegaly
A Colao et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2003)
Improvement of left ventricular hypertrophy and arrhythmias after lanreoticle-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study
G Lombardi et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2002)
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
AJ van der Lely et al.
LANCET (2001)
Reduction of lung distensibility in acromegaly after suppression of growth hormone hypersecretion
F García-Río et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2001)
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
PJ Trainer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Prevalence of the sleep apnea syndrome in acromegaly population
V Weiss et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2000)
分享论文
